{"schema_version":"secwatch.filing_event.v1","accession":"0001764013-22-000114","form_type":"8-K","ticker":"IMVT","cik":"0001764013","company_name":"Immunovant, Inc.","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.958074+00:00","generated_at":"2026-06-23T14:25:01.108904+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunovant to start pivotal Phase 2b in CIDP in H2 2022; Phase 2 in Graves' Disease in early 2023","bullets":["Pivotal Phase 2b trial of batoclimab in CIDP to start H2 2022; initial open-label results expected H1 2024.","Phase 2 trial of batoclimab in Graves' Disease to start early 2023; initial results expected H2 2023.","Batoclimab now in five indications: MG, TED, CIDP, Graves', and wAIHA (trial design pending regulator interaction later 2022).","Data readouts expected every half-year from H2 2023 through H1 2025 across multiple indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001764013-22-000114","json":"https://secwatch.observer/filing/0001764013-22-000114.json","markdown":"https://secwatch.observer/filing/0001764013-22-000114.md","text":"https://secwatch.observer/filing/0001764013-22-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/0001764013-22-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1764013/000176401322000114/imvt-20220907.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:25:01.108904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}